Literature DB >> 10961665

Glatiramer acetate (copolymer-1)-specific, human T cell lines: cytokine profile and suppression of T cell lines reactive against myelin basic protein.

D Dabbert1, S Rösner, M Krämer, U Schöll, H Tumani, M Mäder, F Weber.   

Abstract

Glatiramer acetate (GA), represents an established treatment of relapsing/remitting multiple sclerosis (MS). The mechanisms responsible for the effect of GA are not fully understood. We generated GA-, myelin basic protein (MBP)- and purified protein derivative (PPD)-specific T cell lines from three MS patients and one healthy donor. The GA-specific lines were CD3+, CD4+, CD8- and produced tumor-necrosis-factor-alpha (TNF-alpha), interferon-gamma (IFN-gamma), interleukin-4 (IL-4), interleukin-6 (IL-6) and interleukin-10 (IL-10) after stimulation with GA in the presence of irradiated peripheral blood mononuclear cells. MBP-specific T cell lines showed an identical phenotype and secreted TNF-alpha, IFN-gamma, IL-4, IL-10, but not IL-6. Co-culture experiments demonstrated, that GA-specific T cell lines have the capability to suppress the proliferation of MBP-specific T cell lines.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10961665     DOI: 10.1016/s0304-3940(00)01289-1

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  8 in total

Review 1.  What do we know about the mechanism of action of disease-modifying treatments in MS?

Authors:  Hans-Peter Hartung; Amit Bar-Or; Yannis Zoukos
Journal:  J Neurol       Date:  2004-09       Impact factor: 4.849

2.  Risk-benefit assessment of glatiramer acetate in multiple sclerosis.

Authors:  T Ziemssen; O Neuhaus; R Hohlfeld
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

Review 3.  Seeking balance: Potentiation and inhibition of multiple sclerosis autoimmune responses by IL-6 and IL-10.

Authors:  Sara J Ireland; Nancy L Monson; Laurie S Davis
Journal:  Cytokine       Date:  2015-03-17       Impact factor: 3.861

Review 4.  Multiple sclerosis.

Authors:  David A Hafler
Journal:  J Clin Invest       Date:  2004-03       Impact factor: 14.808

Review 5.  The double-edged sword of autoimmunity: lessons from multiple sclerosis.

Authors:  Anne Lise K Hestvik
Journal:  Toxins (Basel)       Date:  2010-04-22       Impact factor: 4.546

6.  T cell immunity to glatiramer acetate ameliorates cognitive deficits induced by chronic cerebral hypoperfusion by modulating the microenvironment.

Authors:  Li Chen; Yang Yao; Changjuan Wei; Yanan Sun; Xiaofeng Ma; Rongxin Zhang; Xiaolin Xu; Junwei Hao
Journal:  Sci Rep       Date:  2015-09-22       Impact factor: 4.379

Review 7.  Can FDA-Approved Immunomodulatory Drugs be Repurposed/Repositioned to Alleviate Chronic Pain?

Authors:  Kufreobong E Inyang; Joseph K Folger; Geoffroy Laumet
Journal:  J Neuroimmune Pharmacol       Date:  2021-05-26       Impact factor: 4.147

8.  The influence of glatiramer acetate on Th17-immune response in multiple sclerosis.

Authors:  Mikhail Melnikov; Svetlana Sharanova; Anastasiya Sviridova; Vladimir Rogovskii; Nina Murugina; Anna Nikolaeva; Yulia Dagil; Vladimir Murugin; Tatiana Ospelnikova; Alexey Boyko; Mikhail Pashenkov
Journal:  PLoS One       Date:  2020-10-30       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.